HR6364

HR6364, the Kidd’s Stuttering Act, mandates significant changes to Medicaid and CHIP. Specifically, it requires the Secretary to publish changes to core child health quality measures by January 1, 2026, to include screening for childhood-onset fluency disorders, including stuttering, for children aged 2-6. Furthermore, it mandates that Medicaid well-child visits include screening for these disorders starting January 1, 2027, and requires Medicaid and CHIP to cover certain speech therapy services. This is a direct expansion of covered services under major government healthcare programs. The money trail for this bill flows directly into the healthcare services sector, specifically to providers of diagnostic screenings and speech-language pathology services. Medicaid and CHIP are government-funded programs, so the increased coverage translates to guaranteed reimbursement for these services. Companies that operate diagnostic labs, provide speech therapy services, or manage Medicaid and CHIP plans are positioned to capture this new revenue. The bill does not specify a direct appropriation but mandates coverage, meaning states will be required to fund these services through their existing Medicaid and CHIP budgets, with federal matching funds. Historically, expansions of mandated coverage under Medicaid and CHIP have led to increased utilization and revenue for the affected healthcare providers. For example, when the Affordable Care Act (ACA) expanded Medicaid eligibility and mandated coverage for certain services in 2014, healthcare providers and insurers saw a significant increase in patient volume and revenue. While specific stock performance data for a similar, narrowly focused mandate is not readily available, broader Medicaid expansions have consistently benefited managed care organizations and service providers. For instance, following the ACA's Medicaid expansion, companies like Centene ($CNC) and Molina Healthcare ($MOH) experienced sustained growth due to increased enrollment and service utilization. Specific winners include large diagnostic laboratory companies that can develop and implement screening protocols, such as LabCorp ($LH) and Quest Diagnostics ($DGX). Staffing companies specializing in speech-language pathologists, like AMN Healthcare Services ($AMN) and RCM Technologies ($RCMT), will see increased demand for their professionals. Managed care organizations that administer Medicaid and CHIP plans, such as Centene ($CNC), Molina Healthcare ($MOH), and UnitedHealth Group ($UNH) through its Optum and Medicaid segments, will benefit from increased service utilization and potentially higher capitation rates as the scope of covered services expands. There are no clear losers from this legislation, as it primarily expands coverage and creates new revenue opportunities. Next, the bill moves through the House Committee on Energy and Commerce. If it passes the House, it will go to the Senate. The first mandated action, the Secretary publishing changes to core measures, is due by January 1, 2026. Required Medicaid well-child screenings begin January 1, 2027. This provides a clear timeline for implementation and market impact.